The Australian diagnostic and therapeutic radiopharmaceutical company reported revenue of $220.8 million, driven by growth in prostate cancer imagined agent Illuccix.
Telix says result reflects its transition to a sustainable commercial-stage company
August 25, 2023 Latest NewsAustralian Biotech
Latest Video
New Stories
-
Officials talk down the prospect of MFN impact on the PBS
June 4, 2026 - - Latest News -
Novo Nordisk's Marie Krogh Prize returns and crosses the Tasman to back early career women in science
June 4, 2026 - - Latest News -
Study confirms pharmacist led care expands timely access to urinary tract infection treatment and contraception
June 4, 2026 - - BioPharma -
Officials cite company consultation, system changes, and spending approvals to justify delay
June 4, 2026 - - Latest News -
An exchange that reveals the truth of a review that has now become a lot like 'Weekend at Bernie's'
June 3, 2026 - - Latest News -
Invitation confusion clouds Delphi studies and captures medical device sector
June 3, 2026 - - Latest News -
Patient voices take centre stage at the 2026 Patient's Choice Awards
June 3, 2026 - - Latest News

